We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+8.94%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$124B
AUM Growth
+$12.6B
Cap. Flow
+$4.01B
Cap. Flow %
3.23%
Top 10 Hldgs %
24.28%
Holding
4,396
New
293
Increased
2,114
Reduced
1,559
Closed
268

Sector Composition

Rank Sector Weight
1 Technology 15.45%
2 Financials 8.54%
3 Healthcare 8.18%
4 Consumer Discretionary 6.58%
5 Industrials 6.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OGN icon
3926
CALL
Organon & Co
OGN
$3.58B
$50K ﹤0.01%
60,000
+28,800
+92% +$938K
NDRA icon
3927
ENDRA Life Sciences
NDRA
$5.6M
$49K ﹤0.01%
+2
New +$84.9K
VTRS icon
3928
CALL
Viatris
VTRS
$18.7B
$48K ﹤0.01%
48,100
-28,600
-37% -$382K
DBI icon
3929
CALL
Designer Brands
DBI
$321M
$47K ﹤0.01%
39,000
-700
-2% -$10K
UONEK icon
3930
Urban One Class D
UONEK
$23.7M
$47K ﹤0.01%
1,400
SEAC
3931
DELISTED
Seachange International Inc
SEAC
$47K ﹤0.01%
1,455
+205
+16% +$4.42K
GERN icon
3932
Geron
GERN
$1.05B
$46K ﹤0.01%
37,600
-100
-0.3% -$143
INTC icon
3933
CALL
Intel
INTC
$493B
$46K ﹤0.01%
129,800
-10,200
-7% -$521K
LITS
3934
Lite Strategy Inc
LITS
$30.7M
$46K ﹤0.01%
871
-625
-42% -$34.9K
PBW icon
3935
CALL
Invesco WilderHill Clean Energy ETF
PBW
$463M
$46K ﹤0.01%
57,600
+2,200
+4% +$180K
BODI icon
3936
The Beachbody Company
BODI
$45.6M
$46K ﹤0.01%
387
-16
-4% -$3.08K
PGEN icon
3937
Precigen
PGEN
$2.46B
$45K ﹤0.01%
12,209
-5,850
-32% -$25.2K
TDS icon
3938
CALL
Telephone and Data Systems
TDS
$3.84B
$45K ﹤0.01%
89,600
+1,000
+1% +$19.5K
A icon
3939
CALL
Agilent Technologies
A
$42.2B
$44K ﹤0.01%
13,400
CLOV icon
3940
Clover Health Investments
CLOV
$2.33B
$44K ﹤0.01%
+11,928
New +$73.2K
EXK
3941
Endeavour Silver
EXK
$3.14B
$43K ﹤0.01%
+10,275
New +$48.3K
GSK icon
3942
CALL
GSK
GSK
$102B
$43K ﹤0.01%
62,400
-14,640
-19% -$762K
PAVM icon
3943
PAVmed
PAVM
$33.7M
$43K ﹤0.01%
39
-160
-80% -$348K
PII icon
3944
CALL
Polaris
PII
$3.99B
$42K ﹤0.01%
16,000
+800
+5% +$94.2K
PRU icon
3945
CALL
Prudential Financial
PRU
$42.2B
$42K ﹤0.01%
42,200
-2,300
-5% -$250K
LCTX icon
3946
Lineage Cell Therapeutics
LCTX
$283M
$41K ﹤0.01%
16,813
MLSS icon
3947
Milestone Scientific
MLSS
$43M
$41K ﹤0.01%
20,000
+4,000
+25% +$8.8K
POL
3948
DELISTED
Polished.com Inc.
POL
$41K ﹤0.01%
+339
New +$45.6K
BTI icon
3949
CALL
British American Tobacco
BTI
$122B
$40K ﹤0.01%
59,400
ORIO
3950
Orion Digital Corp
ORIO
$18.7M
$40K ﹤0.01%
3,903
-4,372
-53% -$63K

Similar funds

Raymond James & Associates's Q4 2021 Portfolio in Review

As of Q4 2021, Raymond James & Associates held 4,396 positions worth $124B, up 11% from $111B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates deployed $4.01B of net new capital in Q4 2021, opening 293 new positions and adding to 2,114 existing holdings. Its largest new stake was Wells Fargo 7.5% Non Cumv Perp Conv: 14,614 shares worth $21.8M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was iShares MSCI All Country Asia ex Japan ETF, an estimated $80M trimmed.

  • Raymond James & Associates's largest Q4 2021 buy was Wells Fargo 7.5% Non Cumv Perp Conv: 14,614 shares worth $21.8M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q4 2021, an estimated $212M increase.
  • Raymond James & Associates's biggest Q4 2021 reduction was iShares MSCI All Country Asia ex Japan ETF, cutting an estimated $80M.
  • Raymond James & Associates fully exited Kansas City Southern in Q4 2021, selling an estimated $80.8M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $124B portfolio in Q4 2021.
  • Raymond James & Associates opened 293 new positions and closed 268 in Q4 2021.
  • Raymond James & Associates's portfolio value rose 11% quarter-over-quarter to $124B.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.